Detalhe da pesquisa
1.
CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice.
Eur J Haematol
; 106(5): 634-642, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33527479
2.
A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer.
Ann Pharmacother
; 55(11): 1410-1418, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33629601
3.
Trends in the delivery of care to oncology patients in the United States: Emphasis on the role pharmacists on the healthcare team.
J Oncol Pharm Pract
; 27(1): 5-13, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32237957
4.
Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
Ann Pharmacother
; 53(2): 178-185, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30099886
5.
Off-label versus on-label prescribing of oral oncology agents on time to receipt of medication in patients with soft tissue sarcoma.
J Oncol Pharm Pract
; 25(6): 1412-1418, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-30760165
6.
Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.
Support Care Cancer
; 26(4): 1273-1279, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29090385
7.
The regulatory saga of fedratinib.
J Oncol Pharm Pract
; 27(5): 1248-1250, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34013823
8.
Pelvic venous insufficiency: imaging diagnosis, treatment approaches, and therapeutic issues.
AJR Am J Roentgenol
; 204(2): 448-58, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25615769
9.
Angiography in Complex Regional Pain Syndrome.
J Vasc Interv Radiol
; 28(3): 372, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28231921
10.
Pulmonary Vein Varix with Pulmonary Vein Stenosis.
J Vasc Interv Radiol
; 28(1): 147, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28007075
11.
Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes.
Leuk Lymphoma
; 61(10): 2511-2514, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32452280